June/July 2022, Vol 3, No 2

A phase 3 study showed that the addition of cytotoxic chemotherapy to the PD-L1 inhibitor durvalumab was associated with promising antitumor activity as first-line treatment for patients with advanced biliary tract cancer.

Dr Flavio Rocha, Chief of Surgical Oncology and Physician-in-Chief of the Knight Cancer Institute at Oregon Health & Science University, reviewed key abstracts on CCA and other biliary tract cancers presented at the IHPBA Congress.

A letter from the Editor-in-Chief, Milind M. Javle, MD.

In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Francesco Facchinetti from the Gustave Roussy Cancer Campus discussed novel approaches to overcome FGFR resistance in FGFR-altered CCA.

In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Zachariah H. Foda from the Johns Hopkins School of Medicine discussed the role of circulating tumor DNA in early detection and disease monitoring for CCA.

At the Cholangiocarcinoma (CCA) Foundation meeting, Dr Mark Yarchoan from the Johns Hopkins School of Medicine presented his fellowship project focused on deciphering immune micro-environments in molecularly defined CCA subsets.

At the 2022 annual meeting of the Cholangiocarcinoma (CCA) Foundation, a case-based panel discussion focused on multidisciplinary care of CCA.

Rachna T. Shroff, MD, MS, Chief, Section of Gastrointestinal Medical Oncology, University of Arizona Cancer Center, Tucson, reviewed promising clinical data regarding novel targeted therapies currently under clinical investigation for the treatment of cholangiocarcinoma.

At the 2022 Cholangiocarcinoma (CCA) Foundation annual meeting, Dr Shahid Khan, Clinical Senior Lecturer at Imperial College London, discussed the need for correct International Classification of Diseases coding for CCA.